Get startedLog in
    Picture of Coherus Oncology logo

    CHRS — Coherus Oncology News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapNeutral
    All News

    Brief: Coherus Biosciences Announces Divestiture Of YUSIMRY (Adalimumab-Aqvh) In A $40 Mln Upfront All Cash Transaction

    Picture of Coherus Oncology logoCoherus Oncology
    27/06/2024 13:49
    June 27 (Reuters) - Coherus BioSciences Inc  CHRS.O :
    * COHERUS BIOSCIENCES ANNOUNCES DIVESTITURE OF YUSIMRY
(ADALIMUMAB-AQVH) IN A $40 MILLION UPFRONT ALL CASH TRANSACTION
    * COHERUS BIOSCIENCES INC - DIVESTS YUSIMRY TO HKF FOR $40
MILLION
    * COHERUS BIOSCIENCES INC - MEITHEAL TO COMMERCIALIZE
YUSIMRY IN
THE U.S.

Source text for Eikon:  ID:nGNXblcRgv 
Further company coverage:  CHRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Coherus Oncology

    See all news